Home » SGLT2i and GLP‑1 RA Therapy in Type 1 Diabetes and Reno‑Vascular Outcomes: A Real‑World Study
SGLT2i and GLP‑1 RA Therapy in Type 1 Diabetes and Reno‑Vascular Outcomes: A Real‑World Study - TriNetX
SGLT2i and GLP‑1 RA Therapy in Type 1 Diabetes and Reno‑Vascular Outcomes: A Real‑World Study
Feb 15, 2024